Hyaluronic acid and hyaluronidase as possible novel urine biomarkers for the diagnosis of prostate cancer

• Published in: Medical oncology (Northwood, London, England) London, England), 2018-07, Vol.35 (7), p.97-6, Article 97
• Main Authors: Skarmoutsos, Ioannis, Skarmoutsos, Athanasios, Katafigiotis, Ioannis, Tataki, Elisavet, Giagini, Athina, Adamakis, Ioannis, Alamanis, Christos, Duvdevani, Mordechai, Sitaras, Nikolaos, Constantinides, Constantinos
• Format: Article
• Language: English
• Subjects: Aged; Area Under Curve; Biomarkers; Biomarkers, Tumor - urine; Diagnosis, Differential; Early Detection of Cancer - methods; Greece; Hematology; Humans; Hyaluronic acid; Hyaluronic Acid - urine; Hyaluronoglucosaminidase - urine; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Paper; Pathology; Prospective Studies; Prostate cancer; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - urine; Sensitivity and Specificity; Urine
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-018-1157-9

The goal of the study is to examine the possible use of HA (hyaluronic acid) and HAase (hyaluronidase) as novel urine biomarkers for the early diagnosis for prostate cancer (Pca). After a prostatic massage, the urine of 118 high-risk patients for Pca was collected, and the patients were submitted to ultrasound-guided transrectal biopsy. HA and HAase were detected and analyzed with Enzyme-Linked Immunosorbent Assay, and a statistical analysis of the urine levels of the two biomarkers according to the histology results was performed. HAase and HA were independently associated with Pca, and both HAase and HA showed significant predictive ability for prostate cancer. With an optimal cut-off point of 183.71 HAase had 70% sensitivity maintaining at the same time a 55.2% specificity, while the optimal cut-off point for HA was 50.13 with 65% sensitivity and 53.9% specificity. Patients with HAase more than 183.71 ng/ml had 3.67 times greater likelihood for prostate cancer and Patients with HA more than 50.13 ng/ml had 2.31 times greater likelihood for prostate cancer. The need of novel biomarkers that will improve the efficacy of PSA is urgent. HAase and HA showed significant predictive ability for prostate cancer and were independently associated with Pca, and greater levels were associated with greater odds for prostate cancer. To Our Knowledge, this is the first study referring to the detection of HAase and HA as potential urine biomarkers for the early diagnosis of Pca.